AngioDynamics (NASDAQ:ANGO) Updates FY 2020 Earnings Guidance
AngioDynamics (NASDAQ:ANGO) updated its FY 2020 earnings guidance on Wednesday. The company provided earnings per share guidance of $0.25-0.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.25. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $280.58 million.AngioDynamics also updated its FY20 guidance to $0.25-0.30 EPS.
Several analysts have commented on the company. Zacks Investment Research raised Investar from a hold rating to a buy rating and set a $27.00 price objective on the stock in a report on Tuesday, June 4th. BidaskClub raised Westport Fuel Systems from a hold rating to a buy rating in a report on Friday. ValuEngine lowered Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. Finally, TheStreet lowered Upland Software from a b- rating to a c+ rating in a report on Wednesday. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $21.50.
Shares of ANGO opened at $21.89 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.70 and a current ratio of 4.30. AngioDynamics has a 12 month low of $18.11 and a 12 month high of $25.48. The firm has a 50 day simple moving average of $19.57. The firm has a market capitalization of $783.77 million, a price-to-earnings ratio of 26.37 and a beta of 0.69.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.